Advertisement

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience

  • Luca RinaldiEmail author
  • Maria Guarino
  • Alessandro Perrella
  • Pia Clara Pafundi
  • Giovanna Valente
  • Luca Fontanella
  • Riccardo Nevola
  • Barbara Guerrera
  • Natalina Iuliano
  • Michele Imparato
  • Alessio Trabucco
  • Ferdinando Carlo Sasso
  • Filomena Morisco
  • Antonio Ascione
  • Guido Piai
  • Luigi Elio Adinolfi
Original Article
  • 68 Downloads

Abstract

Purpose

The aim of this study was to evaluate the relationship between the liver stiffness measurement and the risk of developing hepatocellular carcinoma (HCC) in HCV cirrhotic patients undergoing new direct-acting antivirals.

Methods

From April 2015 to April 2017, all consecutive HCV cirrhotic patients treated by direct-acting antivirals were enrolled. A liver stiffness measurement was computed at baseline, and an ultrasound evaluation was provided for all patients at baseline and every 6 months until 1 year after the stopping of the antiviral therapy. The diagnosis of HCC was performed according to international guidelines by imaging technique workup.

Results

Two hundred and fifty-eight HCV patients with a diagnosis of cirrhosis were identified. The median liver stiffness was 25.5 kPa. Thirty-five patients developed HCC. Patients were divided into three groups, based on their liver stiffness: < 20 kPa (n = 72), between 20 and 30 kPa (n = 92) and > 30 kPa (n = 94). Compared to the < 20 kPa and 20–30 kPa groups, the > 30 kPa group showed a statistically significant increased risk of HCC (p = 0.019; HR 0.329; 95% CI 0.131–0.830). A ROC curve analysis to assess the overall predictive performance of liver stiffness measurement on the HCC risk was performed. The results allow us to identify a cutoff value of liver stiffness measurement equal to 27.8 kPa, which guarantees the highest sensitivity and specificity (respectively, 72% and 65%).

Conclusions

The data underline that the baseline liver stiffness measurement and ultrasound surveillance is a valuable tool for assessing the risk of HCC in cirrhotic patients undergoing the direct-acting antivirals treatment.

Keywords

Transient elastography Direct-acting antiviral HCC HCV cirrhosis Liver stiffness 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have not any personal or financial conflicts of interest.

References

  1. 1.
    Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.  https://doi.org/10.1053/j.gastro.2014.03.003.CrossRefGoogle Scholar
  2. 2.
    Morisco F, Loperto I, Stroffolini T, et al. Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades. J Med Virol. 2017;89:291–297.  https://doi.org/10.1002/jmv.24635.CrossRefGoogle Scholar
  3. 3.
    Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol. 2013;19:2793–2798.  https://doi.org/10.3748/wjg.v19.i18.2793.CrossRefGoogle Scholar
  4. 4.
    Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403–408.  https://doi.org/10.1136/gut.2005.069153.CrossRefGoogle Scholar
  5. 5.
    Rinaldi L, Valente G, Piai G. Serial liver stiffness measurements and monitoring of liver- transplanted patients in a real-life in clinical practice. Hepat Mon. 2016;16:e41162.  https://doi.org/10.5812/hepatmon.41162.CrossRefGoogle Scholar
  6. 6.
    Adler M, Larocca L, Trovato FM, et al. Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford). 2016;18:678–683.  https://doi.org/10.1016/j.hpb.2016.05.005.CrossRefGoogle Scholar
  7. 7.
    Tatsumi A, Maekawa S, Sato M, et al. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res. 2015;45:523–532.  https://doi.org/10.1111/hepr.12377.CrossRefGoogle Scholar
  8. 8.
    Narita Y, Genda T, Tsuzura H, et al. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy. J Gastroenterol Hepatol. 2014;29:137–143.  https://doi.org/10.1111/jgh.12401.CrossRefGoogle Scholar
  9. 9.
    Feier D, Lupsor Platon M, Stefanescu H, et al. Transient elastography for the detection of hepatocellular carcinoma in viral C liver cirrhosis. Is there something else than increased liver stiffness? J Gastrointestin Liver Dis. 2013;22:283–289.Google Scholar
  10. 10.
    Masuzaki R, Tateishi R, Yoshida H, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42:839–843.CrossRefGoogle Scholar
  11. 11.
    Karlas T, Benckert J, Beer S, et al. Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy? Aliment Pharmacol Ther. 2016;43:543–544.  https://doi.org/10.1111/apt.13479.CrossRefGoogle Scholar
  12. 12.
    AISF Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per lo studio razionale di antivirali diretti della seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilità in Italia.  Available at: http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2016.aspx.
  13. 13.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.  https://doi.org/10.1016/j.jhep.2015.03.025.CrossRefGoogle Scholar
  14. 14.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.  https://doi.org/10.1016/j.jhep.2011.12.001.CrossRefGoogle Scholar
  15. 15.
    Boursier J, Zarski JP, De Ledinghen V, Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies, et al. s. Hepatology. 2013;57:1182–1191.  https://doi.org/10.1002/hep.25993.CrossRefGoogle Scholar
  16. 16.
    Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.  https://doi.org/10.1053/j.gastro.2004.11.018.CrossRefGoogle Scholar
  17. 17.
    Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–1961.  https://doi.org/10.1002/hep.22870.CrossRefGoogle Scholar
  18. 18.
    Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol. 2017;23:6571–6592.  https://doi.org/10.3748/wjg.v23.i36.6571.CrossRefGoogle Scholar
  19. 19.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.  https://doi.org/10.1002/hep.28368.CrossRefGoogle Scholar
  20. 20.
    Di Francia R, Rinaldi L, Troisi A, et al. Effect of anti-oxidant agents in patients with hepatocellular diseases. Eur Rev Med Pharmacol Sci. 2015;19:3993–3995.Google Scholar
  21. 21.
    Pang Q, Qu K, Bi JB, et al. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: systematic review and meta-analysis. World J Gastroenterol. 2015;21:7895–7906.  https://doi.org/10.3748/wjg.v21.i25.7895.CrossRefGoogle Scholar
  22. 22.
    Zhang Z, Zhang Y, Wang W, et al. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. J Surg Res. 2017;210:99–107.  https://doi.org/10.1016/j.jss.2016.11.002.CrossRefGoogle Scholar
  23. 23.
    D’Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532–543.  https://doi.org/10.1002/hep.25606.CrossRefGoogle Scholar
  24. 24.
    Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14:75–82.Google Scholar
  25. 25.
    Kitson MT, Roberts SK, Colman JC, et al. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scand J Gastroenterol. 2015;50:462–469.  https://doi.org/10.3109/00365521.2014.964758.CrossRefGoogle Scholar
  26. 26.
    Abraldes JG, Bureau C, Stefanescu H, Anticipate Investigators, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–2184.  https://doi.org/10.1002/hep.28824.CrossRefGoogle Scholar
  27. 27.
    Rinaldi L, Ascione A, Messina V, et al. Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection. 2017;46:231–238.  https://doi.org/10.1159/000480443.CrossRefGoogle Scholar
  28. 28.
    Elsharkavy A, Alem SA, Fouad R, et al. Changes in liver stiffness measurement and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol. 2017;32:1624–1630.  https://doi.org/10.1111/jgh.13758.CrossRefGoogle Scholar
  29. 29.
    Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37:369–376.  https://doi.org/10.1111/liv.13256.CrossRefGoogle Scholar
  30. 30.
    Perrella A, Izzi A, Punzi R, et al. Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up? Scand J Gastroenteol. 2018;53:1025–1026.  https://doi.org/10.1080/00365521.2018.1495260.CrossRefGoogle Scholar
  31. 31.
    Rinaldi L, Di Francia R, Coppola N, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. World Cancer Res J. 2016;3:e748.Google Scholar
  32. 32.
    Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol. 2018;31:670–679.  https://doi.org/10.20524/aog.2018.0306.Google Scholar
  33. 33.
    Guarino M, Sessa A, Cossiga V, Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver, et al. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J Gastroenterol. 2018;24:2582–2595.  https://doi.org/10.3748/wjg.v24.i24.2582.CrossRefGoogle Scholar
  34. 34.
    Casadei Gardini A, Foschi FG, Conti F, Member of the Bologna DAA Group, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2018;.  https://doi.org/10.1016/j.dld.2018.09.016.Google Scholar
  35. 35.
    Hayes CN, Zhang P, Zhang Y, et al. Molecular mechanisms of hepatocarcinogenesis following sustained virological response in patients with chronic hepatitis C virus infection. Viruses. 2018;.  https://doi.org/10.3390/v10100531.Google Scholar
  36. 36.
    Debes JD, van Tilborg M, Groothuismink ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515–517.  https://doi.org/10.1053/j.gastro.2017.10.035.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Luca Rinaldi
    • 1
    Email author
  • Maria Guarino
    • 2
  • Alessandro Perrella
    • 3
  • Pia Clara Pafundi
    • 1
  • Giovanna Valente
    • 4
  • Luca Fontanella
    • 5
  • Riccardo Nevola
    • 1
  • Barbara Guerrera
    • 1
  • Natalina Iuliano
    • 1
  • Michele Imparato
    • 5
  • Alessio Trabucco
    • 1
  • Ferdinando Carlo Sasso
    • 1
  • Filomena Morisco
    • 2
  • Antonio Ascione
    • 5
  • Guido Piai
    • 4
  • Luigi Elio Adinolfi
    • 1
  1. 1.Department of Advanced Medical and Surgical SciencesUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  2. 2.Department of Clinical Medicine and SurgeryUniversity of Naples “Federico II”NaplesItaly
  3. 3.VII Department of Infectious Diseases and ImmunologyOspedali dei Colli P. O. D. CotugnoNaplesItaly
  4. 4.Department of Medical SciencesA.O.R.N. S. Anna and S. SebastianoCasertaItaly
  5. 5.Department of Internal Medicine, Centre for Liver DiseaseBuon Consiglio Fatebenefratelli HospitalNaplesItaly

Personalised recommendations